Announced Date: 2025-03-21 (March 21, 2025)<\/p>\n\n\n\n
Licensor: Syneron Bio (China)<\/p>\n\n\n\n
Licensee: AstraZeneca\uff08UK\uff09<\/p>\n\n\n\n
Collaboration Object: Co-develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases.<\/p>\n\n\n\n
Main Tech: Syneron Bio’ s TechSynova\u2122 platform<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Collaboration:<\/p>\n\n\n\n
AstraZeneca will gain access to Syneron Bio’s innovative Synova\u2122 platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases, including rare, autoimmune, and metabolic disease.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Deal Detail:<\/p>\n\n\n\n
Upfront payment and near term payment $75 million;<\/p>\n\n\n\n
Development and regulatory, Sales milestone payments up to $3.4 billion;<\/p>\n\n\n\n
Total up to $3.475 billion.<\/p>\n\n\n\n
Additional royalties based on net sales.<\/p>\n\n\n\n
Additionally, Astra Zeneca will invest to Syneron Bio.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:\u00a0<\/p>\n\n\n\n
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing<\/p>\n\n\n\n
https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html<\/a><\/p>\n\n\n\n